[Federal Register Volume 79, Number 227 (Tuesday, November 25, 2014)]
[Notices]
[Pages 70189-70190]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-27850]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

 Centers for Disease Control and Prevention

[30Day-15-14ARR]


Agency Forms Undergoing Paperwork Reduction Act Review

    The Centers for Disease Control and Prevention (CDC) has submitted 
the following information collection request to the Office of 
Management and Budget (OMB) for review and approval in accordance with 
the Paperwork Reduction Act of 1995. The notice for the proposed 
information collection is published to obtain comments from the public 
and affected agencies.
    Written comments and suggestions from the public and affected 
agencies concerning the proposed collection of information are 
encouraged. Your comments should address any of the following: (a) 
Evaluate whether the proposed collection of information is necessary 
for the proper performance of the functions of the agency, including 
whether the information will have practical utility; (b) Evaluate the 
accuracy of the agencies estimate of the burden of the proposed 
collection of information, including the validity of the methodology 
and assumptions used; (c) Enhance the quality, utility, and clarity of 
the information to be collected; (d) Minimize the burden of the 
collection of information on those who are to respond, including 
through the use of appropriate automated, electronic, mechanical, or 
other technological collection techniques or other forms of information 
technology, e.g., permitting electronic submission of responses; and 
(e) Assess information collection costs.
    To request additional information on the proposed project or to 
obtain a copy of the information collection plan and instruments, call 
(404) 639-7570 or send an email to <a href="/cdn-cgi/l/email-protection#06696b644665626528616970"><span class="__cf_email__" data-cfemail="0a6567684a696e69246d657c">[email protected]</span></a>. Written comments and/or 
suggestions regarding the items contained in this notice should be 
directed to the Attention: CDC Desk Officer, Office of Management and 
Budget, Washington, DC 20503 or by fax to (202) 395-5806. Written 
comments should be received within 30 days of this notice.

Proposed Project

    Drug Overdose Response Investigation (DORI) Data Collections--New--
National Center for Injury Prevention and Control (NCIPC), Centers for 
Disease Control and Prevention (CDC).

Background and Brief Description

    State and local health authorities frequently call upon CDC's 
National Center for Injury Prevention and Control (NCIPC) to assist in 
their response to urgent public health problems resulting from drug 
use, misuse, abuse, and overdose. When called, NCIPC supports the 
states and local health authorities by conducting Drug Overdose 
Response Investigations (DORI), which entails a rapid and flexible 
epidemiological response. Urgent requests, such as DORIs, depend on the 
time and resources available, number of persons involved, and other 
circumstances unique to the urgent conditions at hand, and usually 
involve the development of procedures, specific data collection

[[Page 70190]]

instruments, and the collection of critical data.
    This request is for a new generic approval to conduct information 
collections during DORIs. A three-year clearance is requested to 
ensure: (1) Rapid deployment of data collection tools and (2) timely 
information collection of vital information. Of particular interest is 
response to increasing trends in, or changing characteristics of, 
overdose from prescription drugs (with a special interest in opioid 
analgesics such as oxycodone or methadone; benzodiazepines such as 
alprazolam) and/or illicit drugs (e.g., heroin).
    Specifically, this request covers investigative collections with 
the following aims: (1) To understand sudden increases in drug use and 
misuse associated with fatal and nonfatal overdoses; (2) to understand 
the drivers and risk factors associated with those trends; and (3) to 
identify the groups most affected. This will allow CDC to effectively 
advise states on recommended actions to control local epidemics. Thus, 
the ultimate goals of these collections are to minimize adverse health 
consequences, provide epidemiological data collection support to the 
states and, based on the findings from the investigation, appropriately 
assist with implementation of prevention and control measures.
    Data is collected by epidemiologists, psychologists, medical 
professionals, subject matter experts, and biostatisticians. Examples 
of data collection modes that may be employed during DORIs include: 
Archival record abstractions and reviews, face-to-face interviews, 
telephone interviews, web-based questionnaires, and self-administered 
questionnaires.
    For example, information collected through archival chart review 
from hospitals and medical examiners could include demographics, drug 
use history, reported medical and mental health conditions, place of 
overdose, place of death, drug paraphernalia on the scene, mode of 
administration, observers present, naloxone administration, hospital 
admittance, autopsy findings, and toxicology results. Information 
collected through interviews with representatives from agencies 
involved in preventing, intervening, or responding to drug overdose 
could include professional history, personal experience with drug 
overdose cases or investigations, prevention or intervention efforts 
engaged in, and perceptions of characteristics of, or changes in drug 
overdose cases (e.g., transition from opioids to heroin; increasing or 
decreasing rates). Collection of information from nonfatal overdose 
victims, and friends and family of overdose victims could include 
substance use history, prescription drug history, number of providers 
and pharmacies used, pain history, co-occurring health conditions 
(e.g., abnormal snoring indicative of respiratory depression), mental 
health conditions (e.g., depression, anxiety disorders), enrollment in 
drug treatment programs, sources of drugs, route of drug 
administration, and criminal history. Finally, collection of spatial 
information could be obtained through city, county, and state 
government agencies to determine structural and environmental factors 
associated with location of overdose deaths.
    Respondent type will also vary by investigation, but will include 
organizations typically involved in prevention, intervention, and 
response to drug overdose (e.g., public health, law enforcement 
authorities, health systems, and community organizations). Respondents 
also may include victims of non-fatal drug overdoses, as well as family 
and friends of victims.
    During a DORI, data is collected once, with the rare need for 
follow-up. There are no costs to respondents other than their time.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                                   Number of      Average burden
         Type of respondent                  Form name            Number of      responses per     per response
                                                                 respondents       respondent       (in hours)
----------------------------------------------------------------------------------------------------------------
Drug Overdose Response Investigation  Drug Overdose Response            2,700                1               .5
 Participants.                         Investigation Data
                                       Collection Instruments.
----------------------------------------------------------------------------------------------------------------


Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific 
Integrity, Office of the Associate Director for Science, Office of the 
Director, Centers for Disease Control and Prevention.
[FR Doc. 2014-27850 Filed 11-24-14; 8:45 am]
BILLING CODE 4163-18-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>